Trodelvy Redefines First-Line TNBC Treatment with 38% Risk Reduction in Landmark Trial
Breakthrough Results in Aggressive Breast Cancer Gilead Sciences’ Trodelvy has demonstrated unprecedented efficacy as an initial treatment for advanced triple-negative…